‘No correct answer for IBD drugs, but quick treatment needed’
AbbVie's JAK inhibitor Rinvoq (upadacitinib) has expanded its prescribing reach with health insurance coverage for inflammatory bowel disease (IBD). Industry insiders pay attention to Rinvoq's prescribing performance, which will be driven by its …